(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

FYZAMAB

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

FYZAMAB

ST13

US500000090145045

Class

42

Filing

90145045

Registration

7002903

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

37

Latest update

04/21/2023

Trademark type

Word

Nice classes

42

Filing date

08/28/2020

Registration date

03/21/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/21/2023

Last transaction

04/21/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

Drawing code

4

Owner type

99

Owner location

Singapore, SG

Examiner

PIERCE, ALEXANDRA

Law office

M80

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Fyzant Pharma Pte. Ltd.

Representatives

Bruce S. Londa NORRIS MCLAUGHLIN P.A.

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Biomedical research services; research and development in the field of biotechnology; Scientific and technological servicesanalysis in the field of molecular biology; pharmaceutical research and development services; research relating to molecular sciences; research relating to medicine; medical research

Publications

History of USPTO decisions and trademark events.

37 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/21/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

03/21/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

01/03/2023

PUBO

PUBLISHED FOR OPPOSITION

01/03/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

12/14/2022

OTHE

CASE RETURNED TO EXAMINATION

11/23/2022

IUCN

NOTICE OF ALLOWANCE CANCELLED

11/23/2022

JURT

JURISDICTION RESTORED TO EXAMINING ATTORNEY

11/22/2022

PCBG

PETITION TO DIRECTOR - CHANGE BASIS - GRANTED

11/22/2022

APET

ASSIGNED TO PETITION STAFF

11/21/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

11/05/2022

EX3G

SOU EXTENSION 3 GRANTED

11/03/2022

EXT3

SOU EXTENSION 3 FILED

11/03/2022

EEXT

SOU TEAS EXTENSION RECEIVED

11/03/2022

TPAD

TEAS PETITION TO AMEND BASIS RECEIVED

11/03/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

04/14/2022

EX2G

SOU EXTENSION 2 GRANTED

04/12/2022

EXT2

SOU EXTENSION 2 FILED

04/12/2022

EEXT

SOU TEAS EXTENSION RECEIVED

04/12/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

11/02/2021

EX1G

SOU EXTENSION 1 GRANTED

10/29/2021

EXT1

SOU EXTENSION 1 FILED

10/29/2021

EEXT

SOU TEAS EXTENSION RECEIVED

10/29/2021

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

05/04/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

03/09/2021

PUBO

PUBLISHED FOR OPPOSITION

03/09/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

02/17/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/30/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/29/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/29/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

01/29/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

12/30/2020

GNRT

NON-FINAL ACTION E-MAILED

12/30/2020

CNRT

NON-FINAL ACTION WRITTEN

12/30/2020

DOCK

ASSIGNED TO EXAMINER

12/30/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

10/02/2020

NWAP

NEW APPLICATION ENTERED

09/01/2020

Continuous trademark protection

Get notified about every new filing that threatens FYZAMAB or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.